Current Problems in Cardiology
Volume 31, Issue 1 , Pages 8-119 , January 2006

Drug-Eluting Coronary Stents

References 

  1. Al Suwaidi J , Berger PB , Holmes DR . Coronary artery stents . JAMA . 2000;284:1828–1836
  2. Gruentzig A , Senning A , Siegenthaler W . Nonproliferative dilatation of coronary-artery stenosis (percutaneous transluminal coronary angioplasty) . N Engl J Med . 1979;301:61–68
  3. Sigwart U , Puel J , Mirkovitch V , et al.   Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty . N Engl J Med . 1987;316(12):701–706
  4. Al Suwaidi J , Holmes DR , Salam AM , et al.   Impact of coronary artery stents on mortality and nonfatal myocardial infarction (meta-analysis of randomized trials comparing a strategy of routine stenting with that of balloon angioplasty) . Am Heart J . 2004;147(5):815–822
  5. American Heart Association . 2003 heart and stroke statistical update . Dallas, TX: American Heart Association; 2002;
  6. Holmes DR , Vliestra RE , Smith HC , et al.   Restenosis after percutaneous transluminal coronary angioplasty (PTCA) (a report from the PTCA registry of the National Heart, Lung, and Blood Institute) . Am J Cardiol . 1984;53:77C–81C
  7. Serruys PW , Unger F , Sousa JE , et al.   Comparison of coronary artery bypass surgery and stenting for the treatment of multivessel disease . N Engl J Med . 2001;344:1117–1124
  8. Weintraub WS , Ghazzal ZMB , Douglas JS , et al.   Long-term clinical follow-up in patients with angiographic restudy after successful angioplasty . Circulation . 1993;87:831–840
  9. Van Belle E , Abolmaali K , Bauters C , et al.   Restenosis, late vessel occlusion and left ventricular function six months after balloon angioplasty in diabetic patients . J Am Coll Cardiol . 1999;34:476–485
  10. Van Belle E , Ketelers R , Bauters C , et al.   Patency of percutaneous transluminal coronary angioplasty sites at 6-month angiographic follow-up (a key determinant of survival in diabetics after coronary balloon angioplasty) . Circulation . 2001;103:1218–1224
  11. Fischman DL , Leon MB , Baim DS , et al.   A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators . N Engl J Med . 1994;331:496–501
  12. Serruys PW , de Jaegere P , Kiemeneij F , et al.   A comparison of balloon- expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. BENESTENT Study Group . N Engl J Med . 1994;331:489–495
  13. Yokoi H , Kumura T , Nakagawa Y , et al.   Long-term clinical and quantitative angiographic follow-up after the Palmaz- Schatz stent restenosis [abstract] . J Am Coll Cardiol . 1996;27:224A
  14. Weintraub SB , Gebhart SP , Cohen-Bernstein CL , et al.   Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty . Circulation . 1995;91:979–989
  15. Sobel BE . Acceleration of restenosis by diabetes (pathogenetic implications) . Circulation . 2001;103:1185–1187
  16. Moliterno DJ , Yakubov SJ , DiBattiste PM , et al.   Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement (the TARGET follow-up study) . Lancet . 2002;360:355–360
  17. Schomig A , Kastrati A , Elezi S , et al.   Bimodal distribution of angiographic measures of restenosis six months after coronary stent placement . Circulation . 1997;96:3880–3887
  18. Aronson D , Bloomgarden Z , Rayfield EJ . Potential mechanisms promoting restenosis in diabetic patients . J Am Coll Cardiol . 1996;27:528–535
  19. Kastrati A , Schomig A , Elezi S , et al.   Interlesion dependence of the risk for restenosis in patients with coronary stent placement in multiple lesions . Circulation . 1998;97:2396–2401
  20. Ribichini F , Steffenino G , Dellavalle A , et al.   Plasma activity and insertion/deletion polymorphism of angiotensin I-converting enzyme (a major risk factor and a marker of risk for coronary stent restenosis) . Circulation . 1998;97:147–154
  21. van Bockxmeer FM , Mamotte CD , Gibbons FA , et al.   Angiotensin-converting enzyme and apolipoprotein E genotypes and restenosis after coronary angioplasty . Circulation . 1995;92:2066–2071
  22. Kastrati A , Schomig A , Seyfarth M , et al.   PlA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement . Circulation . 1999;99:1005–1010
  23. Hirshfeld JW , Schwartz JS , Jugo R , et al.   Restenosis after coronary angioplasty: a multivariate statistical model to relate lesion and procedure variables to restenosis. The M-HEART investigators . J Am Coll Cardiol . 1991;18:647–656
  24. Elezi S , Kastrati A , Neumann FJ , et al.   Vessel size and long-term outcome after coronary stent placement . Circulation . 1998;98:1875–1880
  25. Foley DP , Melkert R , Serruys PW . Influence of coronary vessel size on renarrowing process and late angiographic outcome after successful balloon angioplasty . Circulation . 1994;90:1239–1251
  26. Rensing BJ , Hermans WR , Deckers JW , et al.   Which angiographic variable best describes functional status 6 months after successful single-vessel coronary balloon angioplasty? . J Am Coll Cardiol . 1993;21:317–324
  27. Kereiakes D , Linnemeier TJ , Baim DS , et al.   Usefulness of stent length in predicting in-stent restenosis (the MULTI-LINK stent trials) . Am J Cardiol . 2000;86:336–341
  28. Bourassa MG , Lesperance J , Eastwood C , et al.   Clinical, physiologic, anatomic and procedural factors predictive of restenosis after percutaneous transluminal coronary angioplasty . J Am Coll Cardiol . 1991;18:368–376
  29. Kuntz RE , Gibson CM , Nobuyoshi M , et al.   Generalized model of restenosis after conventional balloon angioplasty, stenting and directional atherectomy . J Am Coll Cardiol . 1993;21:15–25
  30. Mintz GS , Popma JJ , Pichard AD , et al.   Intravascular ultrasound predictors of restenosis after percutaneous transcatheter coronary revascularization . J Am Coll Cardiol . 1996;27:1678–1687
  31. Moussa I , Moses J , Di Mario C , et al.   Does the specific intravascular ultrasound criterion used to optimize stent expansion have an impact on the probability of stent restenosis? . Am J Cardiol . 1999;83:1012–1017
  32. Kitazume H , Ichiro K , Iwama T , et al.   Repeat coronary angioplasty as the treatment of choice for restenosis . Am Heart J . 1996;132:711–715
  33. Topol EJ , Ellis SG , Fishman J , et al.   Multicenter study of percutaneous transluminal angioplasty for right coronary artery ostial stenosis . J Am Coll Cardiol . 1987;9:1214–1218
  34. Mathias DW , Mooney JF , Lange HW , et al.   Frequency of success and complications of coronary angioplasty of a stenosis at the ostium of a branch vessel . Am J Cardiol . 1991;67:491–495
  35. Berger PB , Holmes DR , Ohman EM , et al.   Restenosis, reocclusion and adverse cardiovascular events after successful balloon angioplasty of occluded versus nonoccluded coronary arteries. Results from the Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) . J Am Coll Cardiol . 1996;27:1–7
  36. Platko WP , Hollman J , Whitlow PL , et al.   Percutaneous transluminal angioplasty of saphenous vein graft stenosis (long-term follow-up) . J Am Coll Cardiol . 1989;14:1645–1650
  37. Savage MP , Douglas JS , Fischman DL , et al.   Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial investigators . N Engl J Med . 1997;337:740–747
  38. Bennett MR . In-stent stenosis (pathology and implications for the development of drug eluting stents) . Heart . 2003;89(2):218–224 Feb
  39. Karthikeyan G , Bhargava B . Prevention of restenosis after coronary angioplasty . Curr Opin Cardiol . 2004;19(5):500–509
  40. Rodriguez AE , Palacios IF , Fernandez MA , et al.   Time course and mechanism of early luminal diameter loss after percutaneous transluminal coronary angioplasty . Am J Cardiol . 1995;76(16):1131–1134
  41. Ross R , Masuda J , Raines EW . Cellular interactions, growth factors, and smooth muscle proliferation in atherogenesis . Ann NY Acad Sci . 1990;598:102–112
  42. Ross R . Atherosclerosis (an inflammatory disease) . N Engl J Med . 1999;340:115–126
  43. Clowes AW , Schwartz SM . Significance of quiescent smooth muscle migration in the injured rat carotid artery . Circ Res . 1985;56:139–145
  44. Rectenwald JE , Moldawer LL , Huber TS , et al.   Direct evidence for cytokine involvement in neointimal hyperplasia . Circulation . 2000;102:1697–1702
  45. Wang X , Romanic AM , Yue TL , et al.   Expression of interleukin-1beta, interleukin-1 receptor, and interleukin-1 receptor antagonist mRNA in rat carotid artery after balloon angioplasty . Biochem Biophys Res Commun . 2000;271:138–143
  46. Hojo Y , Ikeda U , Katsuki T , et al.   Interleukin 6 expression in coronary circulation after coronary angioplasty as a risk factor for restenosis . Heart . 2000;84:83–87
  47. Farb A , Weber DK , Kolodgie FD , et al.   Morphological predictors of restenosis after coronary stenting in humans . Circulation . 2002;105:2974–2980
  48. Kipshidze N , Dangas G , Tsapenko M , et al.   Role of the endothelium in modulating neointimal formation (vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions) . J Am Coll Cardiol . 2004;44:733–739
  49. Karas SP , Gravanis MB , Santoian EC , et al.   Coronary intimal proliferation after balloon injury and stenting in swine (an animal model of restenosis) . J Am Coll Cardiol . 1992;20:467–474
  50. Kornowski R , Hong MK , Tio FO , et al.   In-stent restenosis (contributions of inflammatory responses and arterial injury to neointimal hyperplasia) . J Am Coll Cardiol . 1998;31:224–230
  51. Yutani C , Ishibashi-Ueda H , Suzuki T , et al.   Histologic evidence of foreign body granulation tissue and de novo lesions in patients with coronary stent restenosis . Cardiology . 1999;92:171–177
  52. Koster R , Vieluf D , Kiehn M , et al.   Nickel and molybdenum contact allergies in patients with coronary in-stent restenosis . Lancet . 2000;356:1895–1897
  53. Gaspardone A , Crea F , Versaci F , et al.   Predictive value of C-reactive protein after successful coronary stenting in patients with stable angina . Am J Cardiol . 1998;82:515–518
  54. Hong YJ , Jeong MH , Park HW , et al.   The impact of pre-procedural plasma C-reactive protein on the neointimal hyperplasia after successful coronary artery stenting . J Am Coll Cardiol . 2005;45(3):71A
  55. Sousa JE , Serruys PW , Costa MA . New frontiers in cardiology: drug eluting stents: part I . Circulation . 2003;107:2274–2279
  56. Dobesh PP , Stacy ZA , Ansara AJ , et al.   Drug-eluting stents (a mechanical and pharmacologic approach to coronary artery disease) . Pharmacotherapy . 2004;24(11):1554–1577
  57. Marx SO , Marks AR . Bench to bedside (the development of rapamycin and its application of stent restenosis) . Circulation . 2001;104:852–855
  58. Vasquez EM . Sirolimus (a new agent for prevention of renal allograft rejection) . Am J Health-Syst Pharm . 2000;58:437–438
  59. Braun-Dullaeus RC , Mann MJ , Dzau VJ . Cell cycle progression new therapeutic target for vascular proliferative disease . Circulation . 1998;98:82–89
  60. McKeage K , Murdoch D , Goa KL . The sirolimus-eluting stent (a review of its use in the treatment of coronary artery disease) . Am J Cardiovasc Drugs . 2003;3:211–230
  61. Hooks MA . Tacrolimus, a new immunosuppressant (a review of the literature) . Ann Pharmacother . 1994;28(4):501–511
  62. Curfman GD . Sirolimus-eluting coronary stents . N Engl J Med . 2002;346:1770–1771
  63. Suzuki T , Kopia G , Hayashi S , et al.   Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model . Circulation . 2001;104:1188–1193
  64. Farb A , John M , Acampado E , et al.   Oral everolimus inhibits in-stent neointimal growth . Circulation . 2002;106:2379–2384
  65. Grube E , Sonoda S , Ikeno F , et al.   Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer . Circulation . 2004;109:2168–2171
  66. Buellesfeld L , Grube E . ABT-578-eluting stents . Herz . 2004;29:167–170
  67. Sievers TM , Rossi SJ , Ghobrial RM , et al.   Mycophenolate mofetil . Pharmacotherapy . 1997;17(6):1178–1197
  68. Yamawaki T , Shimokawa H , Kozai T , et al.   Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo . J Am Coll Cardiol . 1998;32:780–786
  69. on behalf of the STEALTH-I Investigators.Grube E, STEALTH-I: Stent Eluting A9 Biolimus Trial in Humans. Presented at EuroPCR 2004, the Paris Course on Revascularization. May 25-28,2004, Paris, France.
  70. Wu K , Leighton JA . Paclitaxel and cell division . N Engl J Med . 2001;344:815
  71. Rowinsky EK , Donehower RC . Paclitaxel (Taxol) . N Engl J Med . 1995;332:1004–1014
  72. Giannakakou P , Robey R , Fojo T , et al.   Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest (molecular determinants of paclitaxel-induced cytotoxicity) . Oncogene . 2001;20:3806–3813
  73. Axel DI , Kunert W , Goggelmann C , et al.   Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery . Circulation . 1997;96:636–645
  74. Moses JW , Kipshidze N , Leon MB . Perspectives of drug-eluting stents (the next revolution) . Am J Cardiovasc Drugs . 2002;2:163–172
  75. Serruys PW , Ormiston JA , Sianos G , et al.   Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial . J Am Coll Cardiol . 2004;44:1363–1367
  76. Sirois MG , Simons M , Edelman ER . Antisense oligonucleotide inhibition of PDGFRbeta receptor subunit expression directs suppression of intimal thickening . Circulation . 1997;95:669–676
  77. Desfaits AC , Raymond J , Muizelaar JP . Growth factors stimulate neointimal cells in vitro and increase the thickness of the neointima formed at the neck of porcine aneurysms treated by embolization . Stroke . 2000;31:498–507
  78. Ding H , Wang R , Marcel R , et al.   Adenovirus-mediated expression of a truncated PDGFbeta receptor inhibits thrombosis and neointima formation in an avian arterial injury model . Thromb Haemost . 2001;86:914–922
  79. Buetow BS , Tappan KA , Crosby JR , et al.   Chimera analysis supports a predominant role of PDGFRbeta in promoting smooth-muscle cell chemotaxis after arterial injury . Am J Pathol . 2003;163:979–984
  80. Gazit A , Yee K , Uecker A , et al.   Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit . Bioorg Med Chem . 2003;11:2007–2018
  81. Banai S , Gertz SD , Gavish L , et al.   Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries . Cardiovasc Res . 2004;64:165–171
  82. Banai S , Wolf Y , Golomb G , et al.   PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine . Circulation . 1998;97:1960–1969
  83. Fishbein I , Waltenberger J , Banai S , et al.   Local delivery of platelet-derived growth factor receptor-specific tyrphostin inhibits neointimal formation in rats . Arterioscler Thromb Vasc Biol . 2000;20:667–676
  84. Fishbein I , Chorny M , Banai S , et al.   Formulation and delivery mode affect disposition and activity of tyrphostin-loaded nanoparticles in the rat carotid model . Arterioscler Thromb Vasc Biol . 2001;21:1434–1439
  85. Yamawaki T , Shimokawa H , Kozai T , et al.   Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo . J Am Coll Cardiol . 1998;32:780–786
  86. Serruys PW . Long-term effects of angiopeptin treatment in coronary angioplasty (reduction of clinical events but not angiographic restenosis) . Circulation . 1995;92:2759–2760
  87. Kwok OH , Chow WH , Lee CH , et al.   First-in-human study of angiopeptin-eluting stents (a quantitative coronary angiography and volumetric intravascular ultrasound study) . J Am Coll Cardiol . 2003;41:6A
  88. de Smet BJ , de Kleijn D , Hanemaaijer R , et al.   Metalloproteinase inhibition reduces constrictive arterial remodeling after balloon angioplasty (a study in the atherosclerotic Yucatan micropig) . Circulation . 2000;101(25):2962–2967
  89. Margolin L , Fishbein I , Banai S , et al.   Metalloproteinase inhibitor attenuates neointima formation and constrictive remodeling after angioplasty in rats (augmentative effect of alpha(v)beta(3) receptor blockade) . Atherosclerosis . 2002;163(2):269–277
  90. Wentzel JJ , Kloet J , Andhyiswara I , et al.   Shear-stress and wall-stress regulation of vascular remodeling after balloon angioplasty (effect of matrix metalloproteinase inhibition) . Circulation . 2001;104(1):91–96
  91. Cherr GS , Motew SJ , Travis JA , et al.   Metalloproteinase inhibition and the response to angioplasty and stenting in atherosclerotic primates . Arterioscler Thromb Vasc Biol . 2002;22(1):161–166
  92. Kipshidze N , Tsapenko M , Iversen P , et al.   Antisense therapy for restenosis following percutaneous coronary intervention . Expert Opin Biol Ther . 2005;5(1):79–89
  93. Kipshidze N , Overlie P , Dunlap T , et al.   First human experience with local delivery of novel antisense AVI-4126 with infiltrator catheter in de novo native and restenotic coronary arteries (six-month clinical and angiographic Follow-up from AVAIL study) . Circulation . 2004;110(suppl III): III-757A
  94. Iozzo RV , Cohen IR , Grassel S , et al.   The biology of perlecan (the multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices) . Biochem J . 1994;302:625–639
  95. Koyama N , Kinsella MG , Wight TN , et al.   Heparan sulfate proteoglycans mediate a potent inhibitory signal for migration of vascular smooth muscle cells . Circ Res . 1998;83:305–313
  96. Jaschke B , Milz S , Vogeser M , et al.   Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration (Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury) . FASEB J . 2004;18:1285–1287
  97. Ruef J , Meshel AS , Hu Z , et al.   Flavopiridol inhibits smooth muscle cell proliferation in vitro and neointimal formation in vivo after carotid injury in the rat . Circulation . 1999;100:659–665
  98. Berk BC , Gordon JB , Alexander RW . Pharmacologic roles of heparin and glucocorticoids to prevent restenosis after coronary angioplasty . J Am Coll Cardiol . 1991;17:111B–117B
  99. Pepine CJ , Hirshfeld JW , Macdonald RG , et al.   A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty. M-HEART Group . Circulation . 1990;81:1753–1761
  100. Lee CW , Chae JK , Lim HY , et al.   Prospective randomized trial of corticosteroids for the prevention of restenosis after intracoronary stent implantation . Am Heart J . 1999;138:60–63
  101. de Scheerder I , Wang K , Wilczek K , et al.   Local methylprednisolone inhibition of foreign body response to coated intracoronary stents . Coron Artery Dis . 1996;7:161–166
  102. Lincoff AM , Furst JG , Ellis SG , et al.   Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model . J Am Coll Cardiol . 1997;29:808–816
  103. Liu XS , Hanet C , Vandormael V , et al.   Study of Anti-restenosis with the BiodivYsio Dexamethasone Eluting Stent (STRIDE)—a multicenter trial . Eur Heart J . 2002;23:26
  104. Patti G , Pasceri V , Carminati P , et al.   Effect of dexamethasone-eluting stents on systemic inflammatory response in patients with unstable angina pectoris or recent myocardial infarction undergoing percutaneous coronary intervention . Am J Cardiol . 2005;95(4):502–505
  105. Ribichini F , Tomai F , DiSciascio G , et al.   Dexamethasone-Eluting Stent Italian Registry in Acute Coronary Syndromes. Preliminary Results of the Nationwide DESIRE Study . Am J Cardiol . 2004;94(suppl 6A):70E
  106. Holmes DR , Savage M , LaBlanche JM , et al.   Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial . Circulation . 2002;106:1243–1250
  107. Tamai H , Katoh O , Suzuki S , et al.   Impact of tranilast on restenosis after coronary angioplasty (tranilast restenosis following angioplasty trial (TREAT)) . Am Heart J . 1999;1:968–975
  108. Tamai H , Katoh K , Yamaguchi T , et al.   The impact of tranilast on restenosis after coronary angioplasty (the Second Tranilast Restenosis Following Angioplasty Trial (TREAT-2)) . Am Heart J . 2002;143(3):506–513
  109. Geraldes P , Sirois MG , Bernatchez PN , et al.   Estrogen regulation of endothelial and smooth muscle cell migration and proliferation (role of p38 and p42/44 mitogen-activated protein kinase) . Arterioscler Thromb Vasc Biol . 2002;22:1585–1590
  110. Abizaid AA , New G , Abizaid AS , et al.   First clinical experience with 17-estradiol-eluting BiodivYsio matrix LO stent to prevent restenosis in de-novo native coronary arteries (six-month clinical outcomes and angiographic follow-up from the EASTER trial) . J Am Coll Cardiol . 2003;41:56A
  111. Costa MA , Sousa JEM , Abizaid AA , et al.   Three-dimensional intravascular ultrasound assessment after the implantation of estrogen-eluting PC-coated stents in human coronary arteries . J Am Coll Cardiol . 2003;41:5A
  112. Airoldi F , DiMario C , Stankovic G , et al.   Estradiol eluting stents for the prevention of restenosis in native coronary arteries (results from the randomized multicentric study EASTER) . J Am Coll Cardiol . 2003;41:56A
  113. Tardif JC , Cote G , Lesperance J , et al.   Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group . N Engl J Med . 1997;6:365–372
  114. Kim W , Jeong MH , Cha KS , et al.   Effect of anti-oxidant (carvedilol and probucol) loaded stents in a porcine coronary restenosis model . Circ J . 2005;69(1):101–106
  115. Yokoi H , Daida H , Kuwabara Y , et al.   Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty (the Probucol Angioplasty Restenosis Trial) . J Am Coll Cardiol . 1997;4:855–862
  116. Hou D , Narciso H , Kamdar K , et al.   Reducing neointimal proliferation by a stent-based delivery of nitric oxide in a porcine carotid overstretch injury model . J Am Coll Cardiol . 2003;41:6A
  117. Scheller B , Schmitt A , Bohm M , et al.   Atorvastatin stent coating does not reduce neointimal proliferation after coronary stenting . Z Kardiol . 2003;92(12):1025–1028
  118. Serruys PW , Foley DP , Jackson G , et al.   A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial . Eur Heart J . 1999;20(1):58–69
  119. Van Belle E , Tio FO , Couffinhal T , et al.   Stent endothelialization. Time course, impact of local catheter delivery, feasibility of recombinant protein administration, and response to cytokine expedition . Circulation . 1997;2:438–448
  120. Van Belle E , Tio FO , Chen D , et al.   Passivation of metallic stents after arterial gene transfer of phVEGF165 inhibits thrombus formation and intimal thickening . J Am Coll Cardiol . 1997;6:1371–1379
  121. Asahara T , Bauters C , Pastore C , et al.   Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery . Circulation . 1995;11:2793–2801
  122. Matsumoto Y , Shimokawa H , Morishige K , et al.   Reduction in neointimal formation with a stent coated with multiple layers of releasable heparin in porcine coronary arteries . J Cardiovasc Pharmacol . 2002;39(4):513–522
  123. Alt E , Haehnel I , Beilharz C , et al.   Inhibition of neointima formation after experimental coronary artery stenting (a new biodegradable stent coating releasing hirudin and the prostacyclin analogue iloprost) . Circulation . 2000;101:1453–1458
  124. Babapulle MN , Eisenberg MJ . Coated stents for the prevention of restenosis (Part I) . Circulation . 2002;106(21):2734–2740
  125. Babapulle MN , Eisenberg MJ . Coated stents for the prevention of restenosis (Part II) . Circulation . 2002;106(22):2859–2866
  126. Van der Giessen WJ , Lincoff AM , Schwart RS , et al.   Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries . Circulation . 1996;94:1690–1697
  127. Rogers CD . Drug-eluting stents (clinical perspectives on drug and design differences) . Rev Cardiovasc Med . 2005;6(suppl 1):S3–S12
  128. Hwang C-W , Wu D , Edelman ER . Physiological transport forces govern drug delivery distribution for stent-based delivery . Circulation . 2001;104:600–605
  129. Sousa JE , Costa MA , Abizaid A , et al.   Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries (a quantitative coronary angiography and three-dimensional intravascular ultrasound study) . Circulation . 2001;103:192–195
  130. Sousa JE , Costa MA , Abizaid AC , et al.   Sustained suppression of neointimal proliferation by sirolimus-eluting stents (one-year angiographic and intravascular ultrasound follow-up) . Circulation . 2001;104:2007–2011
  131. Sousa JE , Costa MA , Sousa A , et al.   Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries . Circulation . 2003;107:381–383
  132. Sousa JE. Long-term follow-up, additional subset analysis and final perspective: the FIM 4-year results. Presented at the 53rd annual scientific session of the American College of Cardiology, New Orleans, LA, March 6, 2004.
  133. Morice MC , Serruys PW , Sousa JE , et al.   A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization . N Engl J Med . 2002;346:1773–1780
  134. Serruys PW, Degertekin M, Tanabe K, et al. Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (randomized study with the sirolimus-eluting velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions) trial. Circulation 202;106:798-803.
  135. Regar E , Serruys PW , Bode C , et al.   Angiographic findings of the multicenter randomized study with the sirolimus-eluting BX velocity balloon-expandable stent (RAVEL). Sirolimus-eluting stents inhibit restenosis irrespective of the vessel size . Circulation . 2002;106:1949–1956
  136. Tanabe K , Serruys PW , Degertekin M , et al.   Fate of side branches after coronary arterial sirolimus-eluting stent implantation . Am J Cardiol . 2002;90:937–941
  137. Fajadet J , Morice MC , Bode C , et al.   Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents (three-year results of the RAVEL trial) . Circulation . 2005;111(8):1040–1044
  138. Moses JW , Leon MB , Popma JJ , et al.   Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery . N Engl J Med . 2003;349:1315–1323
  139. Holmes DR , Leon MB , Moses JW , et al.   Analysis of 1-year clinical outcomes in the SIRIUS trial (a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis) . Circulation . 2004;109(5):634–640
  140. Kereiakes D , Moses JW , Leon MB , et al.   Durable clinical benefit following CYPHER coronary stent deployment (SIRIUS study 2-year results [abstr]) . Circulation . 2003;108(suppl IV): IV-532
  141. Leon MB , Holmes DR , Simonton C , et al.   The impact of sirolimus-eluting stents in diabetics (results from the SIRIUS trial) . J Am Coll Cardiol . 2003;41(suppl II):54A
  142. Cohen DJ , Bakhai A , Shi C , et al.   Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses (results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial) . Circulation . 2004;110(5):508–514
  143. Schofer J , Schluter M , Gershlick AH , et al.   Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries (double-blind, randomised controlled trial (E-SIRIUS)) . Lancet . 2003;362:1093–1099
  144. Schofer J. E-SIRIUS Direct Stent versus Predilatation Substudy. Presented by at the European Society of Cardiology Congress, September 2003, Vienna, Austria.
  145. Schampaert E , Cohen EA , Schluter M , et al.   The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS) . J Am Coll Cardiol . 2004;43(6):1110–1115
  146. Lemos PA , Serruys PW , van Domburg RT , et al.   Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the “real world” (The Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry) . Circulation . 2004;109:190–195
  147. Lemos PA , Hoye A , Goedhart D , et al.   Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients . Circulation . 2004;109:1366–1370
  148. van Domburg RT , Ong AT , Lemos PA , et al.   Two year outcome of the RESEARCH registry . J Am Coll Cardiol . 2005;45(3):74A
  149. for the International e-Cypher Investigators.Urban P, The e-Cypher registry: sirolimus-eluting stent in routine clinical practice. Presented at EuroPCR: The Paris Course on Revascularization. May 25-28, 2004, Paris, France.
  150. Iakovou I , Ge L , Sangiorgi G , et al.   Sirolimus-eluting stents versus bare metal stents in unselected lesions (follow-up results from the Milan registry) . J Am Coll Cardiol . 2005;45(3):66A
  151. Laskey WK , Williams DO , Vlachos HA , et al.   Changes in the practice of percutaneous coronary intervention (comparison of enrollment waves in the National Heart, Lung, and Blood Institute (NHBLI) dynamic registry) . Am J Cardiol . 2001;87:964–969
  152. Costa MA , Perin E , Berger P , et al.   Final Report of the Cypher Stent U.S. Post Marketing Surveillance Registry . J Am Coll Cardiol . 2005;45(3):72A
  153. Grube E , Silber S , Hauptamann KE , et al.   TAXUS I (six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions) . Circulation . 2003;107:38–42
  154. Colombo A , Drzewiecki J , Banning A , et al.   Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stent for coronary artery lesions . Circulation . 2003;108:788–794
  155. Colombo A. TAXUS II: two-year results with angiographic and IVUS follow-up. Presented at Late-Breaking Clinical Trials during Transcatheter Cardiovascular Therapeutics Conference, September 2004.
  156. Stone GW , Ellis SG , Cox DA , et al.   A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease . N Engl J Med . 2004;350(3):221–231
  157. Stone GW , Ellis SG , Cox DA , et al.   One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent (the TAXUS-IV trial) . Circulation. . 2004;109(16):1942–1947
  158. Stone GW. TAXUS IV: two-year results from the pivotal prospective randomized trial of the slow-release polymer-based paclitaxel-eluting stent. Presented at the 2004 Transcatheter Cardiovascular Therapeutics conference, Washington, DC.
  159. Tanabe K , Serruys PW , Grube E , et al.   TAXUS III Trial (in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation) . Circulation . 2003;107:559–564
  160. Grube E , Serruys PW , Russell ME . TAXUS III Three-year clinical results (a feasibility study of the polymer-based, paclitaxel-coated stent for the treatment of in-stent restenosis) . J Am Coll Cardiol . 2005;45(3):66A
  161. TAXUS VI: a randomized trial of moderate-rate-release, polymer-based, paclitaxel-eluting stent for the treatment of longer lesions—9-month clinical results presented by E. Grube at the EURO-PCR meeting, May 2004, Paris.
  162. TAXUS V. Presented by Gregg W. Stone at the 2005 ACC Scientific Sessions, Orlando, FL, USA.
  163. Park SJ , Shim WH , Ho DS , et al.   A paclitaxel-eluting stent for the prevention of coronary restenosis . N Engl J Med . 2003;348:1537–1545
  164. Gershlick A , Scheerder ID , Chevalier B , et al.   Inhibition of restenosis with a paclitaxel-eluting polymer free coronary stent (the European evaluation of paclitaxel-eluting stent (ELUTES) trial) . Circulation . 2004;109:487–493
  165. Lansky AJ , Costa RA , Mintz GS . Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions (angiographic follow-up of the DELIVER clinical trial) . Circulation . 2004;109(16):1948–1954
  166. DELIVER II Registry. Presented by Eberhard Grube at the European Society of Cardiology Congress, September 2003, Vienna, Austria.
  167. Ishizaka N , Issiki T , Saeki F , et al.   Angiographic follow-up after successful percutaneous coronary angioplasty for chronic total coronary occlusion . Am Heart J . 1994;127:8–12
  168. Ivanhoe RJ , Weintraub WS , Douglas JS , et al.   Percutaneous transluminal coronary angioplasty of chronic total occlusions . Circulation . 1992;85:106–115
  169. Violaris AG , Melkert R , Serruys PW . Long-term luminal renarrowing after successful elective coronary angioplasty of total occlusions . Circulation . 1995;91:2140–2150
  170. Sirnes PA , Golf S , Myreng Y , et al.   Stenting in Chronic Coronary Occlusion (SICCO) . J Am Coll Cardiol . 1996;28:1444–1451
  171. Hoher M , Wohrle J , Grebe OC , et al.   A randomized trial of elective stenting after balloon recanalization of chronic total occlusions . J Am Coll Cardiol . 1999;34:722–729
  172. Rubartelli P , Niccoli L , Verna E , et al.   for the Gruppo Italiano di Studio Sullo Stent Nelle Occlusioni Coronariche (GISSOC). Stent implantation versus balloon angioplasty in chronic coronary occlusions . J Am Coll Cardiol . 1998;32:90–96
  173. Buller CE , Dzavik V , Carere RG , et al.   Primary stenting versus balloon angioplasty in occluded coronary arteries (the Total Occlusion Study of Canada (TOSCA)) . Circulation . 1999;100:236–242
  174. Sievert H , Rohde S , Utech A , et al.   Stent or angioplasty after recanalization of chronic coronary occlusions? . Am J Cardiol . 1999;84:386–390
  175. Hancock J , Thomas MR , Holmberg S , et al.   Randomized trial of elective stenting after successful percutaneous transluminal coronary angioplasty of occluded coronary arteries . Heart . 1998;79:18–23
  176. Olivari Z , Rubartelli P , Piscione F , et al.   Immediate results and one-year clinical outcome after percutaneous coronary interventions in chronic total occlusions . J Am Coll Cardiol . 2003;41:1672–1678
  177. Nakamura S , Muthusamy TS , Bae JH , et al.   Impact of sirolimus-eluting stent on the outcome of patients with chronic total occlusions . Am J Cardiol . 2005(Jan 15);;95(2):161–166
  178. Hoye A , Tanabe K , Lemos PA , et al.   Significant reduction in restenosis after the use of sirolimus-eluting stents in the treatment of chronic total occlusions . J Am Coll Cardiol . 2004;43(11):1954–1958
  179. Lotan C , Almagor Y , Wijns W , et al.   Sirolimus-eluting stent in chronic total occlusion. Presented at EuroPCR: The Paris Course on Revascularization . 2004; Paris, France May 25-28
  180. Ge L , Iakovou I , Sangiorgi GM , et al.   Immediate and mid-term outcome of sirolimus-eluting stent implantation for chronic total occlusion lesions . J Am Coll Cardiol . 2005;45(3):47A
  181. Cioppa A , Salemme L , Ambrosini V , et al.   Recanalization of chronic total coronary occlusion with sirolimus-eluting stent: eight-months angiographic follow-up. Single center experience . J Am Coll Cardiol . 2005;45(3):27A
  182. R. Stuart Dickson Institute for Health Studies. Data on file. Charlotte, NC: R. Stuart Dickson Institute for Health Studies. Carolinas HealthCare System.
  183. Lotan C, Urban P, Guagliumi G, et al. Treatment of chronic total occlusion with the sirolimus-eluting stent—initial results from the e-CYPHER registry. Program and abstracts from the European Society of Cardiology Congress 2004; August 28-September 1, 2004; Munich, Germany.
  184. Werner GS . Successful prevention of lesion recurrence in chronic total coronary occlusions treated with a paclitaxel-eluting polymer-based stent (Long-term results from the Paclitaxel in Chronic Total Occlusion (PACTO) Study) . J Am Coll Cardiol . 2005;45(3):27A
  185. Sunao Nakamura S , Tamil Selvan Muthusamy TS , Bae JH , et al.   Comparison of efficacy and safety between sirolimus-eluting stent (Cypher™) and paclitaxel-eluting stent (TAXUS™) on the outcome of patients with chronic total occlusions (multicenter registry in Asia) . J Am Coll Cardiol . 2005;45(3):48A
  186. Khoja A , Ozbek C , Bay W , Heisel A . Trouser-like stenting (a new technique for bifurcation lesions) . Cathet Cardiovasc Diagn . 1997;41(2):192–196
  187. Baim DS . Is birfurcation stenting the answer? . Catheter Cardiovasc Diagn . 1996;37:314–316
  188. Al Suwaidi J , Berger PB , Rihal CS , et al.   Immediate and long term outcome of intracoronary stent implantation for true bifurcation lesions . J Am Coll Cardiol . 2000;35:929–936
  189. Pan M , Suarez de Lezo J , Medina A , et al.   Simple and complex stent strategies for bifurcated coronary arterial stenosis involving the side branch origin . Am J Cardiol . 1999;83:1320–1325
  190. Yamashita T , Nishida T , Adamian MG , et al.   Bifurctaion lesions: two stents versus one stent: immediate and follow-up results . J Am Coll Cardiol . 2000;35:1145–1151
  191. Colombo A , Moses JW , Morice MC , et al.   Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions . Circulation . 2004;109(10):1244–1249
  192. Pan M , de Lezo JS , Medina A , et al.   Rapamycin-eluting stents for the treatment of bifurcated coronary lesions (a randomized comparison of a simple versus complex strategy) . Am Heart J . 2004;148(5):857–864
  193. Ge L , Tsagalou E , Iakovou I , et al.   In-hospital and nine-month outcome of treatment of coronary bifurcational lesions with sirolimus-eluting stent . Am J Cardiol . 2005;95(6):757–760
  194. Tanabe K , Hoye A , Lemos PA , et al.   Restenosis rates following bifurcation stenting with sirolimus-eluting stents for de novo narrowings . Am J Cardiol . 2004;94(1):115–118
  195. Lefèvre TL , Louvard Y , Dumas P , et al.   Evaluation of sirolimus eluting stents for the treatment of bifurcation lesions (a real world study) . J Am Coll Cardiol . 2005;45(3):56A
  196. Colombo A , Stankovic G , Orlic D , et al.   Modified T-stenting technique with crushing for bifurcation lesions (immediate results and 30-day outcome) . Catheter Cardiovasc Interv . 2003;60(2):145–151
  197. Airoldi F , Colombo A , Michev I , et al.   Sirolimus eluting stents implantation in bifurcational coronary artery lesions utilizing the ‘Crush’ technique (immediate and mid term outcome) . J Am Coll Cardiol . 2005;45(3):47A
  198. Sawhney N , Price MJ , Damani S , et al.   Treatment of bifurcation lesions with sirolimus—eluting stents using the “Crush” and “V” techniques. Procedural and clinical outcomes . J Am Coll Cardiol . 2005;45(3):66A
  199. Ge L , Iakovou I , Tsagalou E , et al.   Thrombosis after drug-eluting stent implantation in bifurcational lesions by crush stent technique . J Am Coll Cardiol . 2005;45(3):65A
  200. O’Keefe JH , Hartzler GO , Rutherford BD , et al.   Left main coronary angioplasty . Am J Cardiol . 1989;64:144–147
  201. Eldar M , Schulhoff N , Herz I , et al.   Results of percutaneous transluminal angioplasty of the left main coronary artery . Am J Cardiol . 1991;68:255–256
  202. Hartzler GO , Rutherford BD , McConahay DR , et al.   “High-risk” percutaneous transluminal coronary angioplasty . Am J Cardiol . 1988;61:33G–37G
  203. Lopez JJ , Ho KK , Stoler RC , et al.   Percutaneous treatment of protected and unprotected left main coronary stenoses with new devices . J Am Coll Cardiol . 1997;29:345–352
  204. Ellis SG , Tamai H , Nobuyoshi M , et al.   Contemporary percutaneous treatment of unprotected left main coronary stenoses . Circulation . 1997;96:3867–3872
  205. Park SJ , Park SW , Hong MK , et al.   Stenting of unprotected left main coronary artery stenoses . J Am Coll Cardiol . 1998;31:37–42
  206. Wong P , Wong V , Tse KK , et al.   A prospective study of elective stenting in unprotected left main coronary disease . Catheter Cardiovasc Interv . 1999;46:153–159
  207. Arampatzis CA , Lemos PA , Tanabe K , et al.   Effectiveness of sirolimus-eluting stent for treatment of left main coronary artery disease . Am J Cardiol . 2003;92(3):327–329
  208. Arampatzis CA , Lemos PA , Hoye A , et al.   Elective sirolimus-eluting stent implantation for left main coronary artery disease (six-month angiographic follow-up and 1-year clinical outcome) . Catheter Cardiovasc Interv . 2004;62(3):292–296
  209. Costa MA , Perin E , Berger P , et al.   Initial US experience on treatment of left main disease with sirolimus-eluting stents (insights from the e-Cypher post-marketing surveillance study) . J Am Coll Cardiol . 2005;45(3):54A
  210. Di Salvo ME , Garro N , Petralia A , et al.   Drug eluting stent in the treatment of unprotected left main disease (immediate results and six-month angiographic follow-up) . J Am Coll Cardiol . 2005;45(3):54A
  211. Sheiban I , Moretti C , Lombardo C , et al.   Drug-eluting stents vs bare metal stents in the treatment of unprotected left main coronary artery disease (immediate and long term clinical outcome) . J Am Coll Cardiol . 2005;45(3):54A
  212. Nakamura S , Muthsamy TS , Bae JH , et al.   Durable clinical benefit following sirolimus-eluting stent deployment on the outcome of patients with unprotected left main coronary arteries (multicenter registry two-year results) . J Am Coll Cardiol . 2005;45(3):54A
  213. Lefèvre L , Silvestri M , Darremont O , et al.   Preliminary Results of the Left Main TAXUS Pilot Study . J Am Coll Cardiol . 2005;45(3):53A
  214. Park SJ , Kim YH , Lee BK , et al.   Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis (comparison with bare metal stent implantation) . J Am Coll Cardiol . 2005;45(3):351–356
  215. Chieffo A , Stankovic G , Bonizzoni E . Early and mid-term results of drug-eluting stent implantation in unprotected left main . Circulation . 2005;111(6):791–795
  216. Valgimigli M , van Mieghem CA , Ong AT , et al.   Short- and long-term clinical outcome after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease (insights from the Rapamycin-Eluting and Taxus Stent Evaluated At Rotterdam Cardiology Hospital registries (RESEARCH and T-SEARCH)) . Circulation . 2005;111(11):1383–1389
  217. Crosby IK , Wellons HAJ , Taylor GJ , et al.   Critical analysis of the preoperative and operative predictors of aortocoronary bypass patency . Ann Surg . 1981;193:743–751
  218. O’Connor NJ , Morton JR , Birkmeyer JD , et al.   Effect of coronary artery diameter in patients undergoing coronary bypass surgery . Circulation . 1996;93:652–655
  219. Foley DP , Melkert R , Serruys PW , et al.   Influence of vessel size on renarrowing process and late angiographic outcome after successful balloon angioplasty . Circulation . 1994;90:1239–1251
  220. Schunkert H , Harrel L , Palacios IF . Implications of small reference vessel diameter in patients undergoing percutaneous coronary revascularization . J Am Coll Cardiol . 1999;34:40–48
  221. Hirshfeld JW , Schwartz JS , Jugo R , et al.   Restenosis after coronary angioplasty (a multivariate statistical model to relate lesion and procedure variables to restenosis) . J Am Coll Cardiol . 1991;18:647–656
  222. Elezi S , Kastrati A , Neumann FJ , et al.   Vessel size and long-term outcome after coronary stent placement . Circulation . 1998;98:1875–1880
  223. Akiyama T , Moussa I , Reimers B , et al.   Angiographic and clinical outcome following coronary stenting of small vessels (a comparison with coronary stenting in large vessels) . J Am Coll Cardiol . 1998;32:1610–1618
  224. Mehilli J , Kastrati A , Dirschinger J , et al.   Differences in prognostic factors and outcomes between women and men undergoing coronary artery stenting . JAMA . 2000;284:1799–1805
  225. Holmes DR , Kereiakes DJ . The approach to small vessels in the era of drug-eluting stents . Rev Cardiovasc Med . 2005;6(suppl 1):S31–S37
  226. Guagliumi G , Sousa JE , Voudris V , et al.   Optimal implantation technique for sirolimus-eluting stents in small vessels with de novo coronary artery lesions (a comparison between the SIRIUS and SVELTE trials) . Am J Cardiol . 2004;94(suppl 6A):65E
  227. Ardissino D , Cavallini C , Bramucci E , et al.   Sirolimus-eluting versus uncoated stents for prevention of restenosis in small arteries (a randomized trial) . JAMA . 2004;292:2727–2734
  228. Guyon P , Urban P , Schofer J , et al.   The impact of sirolimus-eluting stent implantation in small vessel angioplasty (a report from the e-CYPHER registry) . J Am Coll Cardiol . 2005;45(3):64A
  229. Lemos PA , Arampatzis CA , Saia F , et al.   Treatment of very small vessels with 2.25-mm diameter sirolimus-eluting stents (from the RESEARCH Registry) . Am J Cardiol . 2004;93:633–636
  230. Hirshfeld JW , Schwartz JS , Jugo R , et al.   Restenosis after coronary angioplasty . J Am Coll Cardiol . 1991;18:647–656
  231. Kobayashi Y , De Gregorio J , Kobayashi N , et al.   Stented segment length as an independent predictor of restenosis . J Am Coll Cardiol . 1999;34:651–659
  232. Kornowski R , Mehran R , Hong MK , et al.   Procedural results and late clinical outcomes after placement of three or more stents in single coronary lesions . Circulation . 1998;97:1355–1361
  233. Serruys PW , Foley DP , Suttorp MJ , et al.   A randomized comparison of the value of additional stenting after optimal balloon angioplasty for long coronary lesions (final results of the additional value of NIR stents for treatment of long coronary lesions (ADVANCE) study) . J Am Coll Cardiol . 2002;39:393–399
  234. Hoffmann R , Herrmann G , Silber S , et al.   Randomized comparison of success and adverse event rates and cost effectiveness of one long versus two short stents for treatment of long coronary narrowings . Am J Cardiol . 2002;90:460–464
  235. Oemrawsingh PV , Mintz GS , Schalij MJ , et al.   Intravascular ultrasound guidance improves angiographic and clinical outcome of stent implantation for long coronary artery stenoses (final results of a randomized comparison with angiographic guidance (TULIP Study)) . Circulation . 2003;107:62–67
  236. Schalij MJ , Udayachalerm W , Oemrawsingh P , et al.   Stenting of long coronary artery lesions (initial angiographic results and 6-month clinical outcome of the micro stent II-XL) . Cathet Cardiovasc Interventions . 1999;48:105–112
  237. Kornowski R , Bhargava B , Fuchs S , et al.   Procedural results and late clinical outcomes after percutaneous interventions using long (> or = 25 mm) versus short (< 20 mm) stents . J Am Coll Cardiol . 2000;35(3):612–618
  238. Degertekin M , Arampatzis CA , Lemos PA , et al.   Very long sirolimus-eluting stent implantation for de novo coronary lesions . Am J Cardiol . 2004;93(7):826–829
  239. Hong MK. Long-DES—A Multicenter Prospective Nonrandomized Registry Study for drug-eluting stents in very long coronary lesions (Cypher vs Taxus). Presented at Transcatheter Therapeutics 2004, Sept. 30, Washington, DC.
  240. Park SJ , Kim YH , Lee CW , et al.   Stent length as a predictor of restenosis after long sirolimus-eluting stent implantation . J Am Coll Cardiol . 2005;45(3):64A
  241. Nakamura S , Muthusamy TS , Bae JH , et al.   One-year clinical outcome of Cypher sirolimus-eluting stents in patients with long coronary lesions (multicenter registry in Asia) . J Am Coll Cardiol . 2005;45(3):65A
  242. Barsness GW , Buller C , Ohman EM , et al.   Reduced thrombus burden with abciximab delivered locally before percutaneous intervention in saphenous vein grafts . Am Heart J . 2000;139:824–829
  243. Piana RN , Paik GY , Moscucci M , et al.   Incidence and treatment of “no-reflow” after percutaneous coronary intervention . Circulation . 1994;89:2514–2518
  244. de Feyter PJ , van Suylen RJ , de Jaegere PP , et al.   Balloon angioplasty for the treatment of lesions in saphenous vein bypass grafts . J Am Coll Cardiol . 1993;21:1539–1549
  245. Dorros G , Johnson WD , Tector AJ , et al.   Percutaneous transluminal coronary angioplasty in patients with prior coronary artery bypass grafting . J Thorac Cardiovasc Surg . 1984;87:17–26
  246. Brener SJ , Ellis SG , Apperson-Hansen C , et al.   Comparison of stenting and balloon angioplasty for narrowings in aortocoronary saphenous vein conduits in place for more than five years . Am J Cardiol . 1997;79:13–18
  247. Bhargava B , Kornowski R , Mehran R , et al.   Procedural results and intermediate clinical outcomes after multiple saphenous vein graft stenting . J Am Coll Cardiol . 2000;35:389–397
  248. Piana RN , Moscucci M , Cohen DJ , et al.   Palmaz-Schatz stenting for treatment of focal vein graft stenosis . J Am Coll Cardiol . 1994;23:1296–1304
  249. Savage MP , Douglas JS , Fischman DL , et al.   Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts . N Engl J Med . 1997;337:740–747
  250. Hanekamp CE , Koolen JJ , Den Heijer P , et al.   Randomized study to compare balloon angioplasty and elective stent implantation in venous bypass grafts (the Venestent study) . Catheter Cardiovasc Interv . 2003;60(4):452–457
  251. Simonton CA , Brodie BR , Wilson BH . Drug-eluting stents for emerging treatment strategies in complex lesions . Rev Cardiovasc Med . 2005;6(suppl 1):S38–S47
  252. Chu W , Rha SW , Torguson R , et al.   Efficacy of sirolimus-eluting stents in comparison to bare metal stents for saphenous vein graft intervention . J Am Coll Cardiol . 2005;45(3):26A
  253. Sharma A , Minutello RM , Yang F , et al.   One-year clinical follow up of sirolimus-eluting stents in the treatment of saphenous vein graft disease . J Am Coll Cardiol . 2005;45(3):25A
  254. Ge L , Iakovou I , Sangiorgi GM , et al.   Treatment of saphenous vein grafts lesions with drug-eluting stents (immediate and mid-term outcome) . J Am Coll Cardiol . 2005;45(3):25A
  255. Rajeev AG , Surabhi S , Gupta V , et al.   In-hospital outcomes and trends in usage of drug-eluting stents in aortocoronary bypass grafts (a report from the American College of Cardiology—National Cardiovascular Data Registry(ACC-NCDR)) . J Am Coll Cardiol . 2005;45(3):25A
  256. Perin EC , Costa MA , Cohen S , et al.   CYPHER Sirolimus-eluting Bx Velocity stent is a safe and effective treatment for arterial and saphenous vein bypass grafts . J Am Coll Cardiol . 2005;45(3):26A
  257. Sousa JE , Abizaid A , Gershlick AH , et al.   Real world use of sirolimus-eluting stents in saphenous vein graft disease (data from the e-CYPHER Registry) . J Am Coll Cardiol . 2005;45(3):26A
  258. Mishkel GJ , Goswami NJ , Gill JB , et al.   An evaluation of drug eluting stents in saphenous vein grafts . J Am Coll Cardiol . 2005;45(3):26A
  259. Serruys PW , Lemos PA , van Hout BA , et al.   Sirolimus eluting stent implantation for patients with multivessel disease (rationale for the Arterial Revascularization Therapies Study part II (ARTS II)) . Heart . 2004;90:995–998
  260. Serruys PW , Unger F , Sousa JE , et al.   Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease . N Engl J Med . 2001;344(15):1117–1124
  261. Serruys P. A multicenter, prospective registry of multivessel stenting with the polymer-based, sirolimus-eluting stent—long-term results (ARTS-II). Paper presented at the Transcatheter Therapeutics 2004, 27 September, Washington, DC, USA.
  262. Arterial Revascularization Therapies Study Part II: Sirolimus-eluting stents for the treatment of patients with multivessel de novo coronary artery lesions (ARTS-II). Presented by Dr. Patrick W. Serruys at the 2005 ACC Scientific Sessions, Orlando, FL, USA.
  263. Orlic D , Bonizzoni E , Stankovic G , et al.   Treatment of multivessel coronary artery disease with sirolimus-eluting stent implantation (immediate and mid-term results) . J Am Coll Cardiol . 2004;43:1154–1160
  264. Mehran R , Dangas G , Abizaid A , et al.   Angiographic patterns of in-stent restenosis (classification and implications for long-term outcome) . Circulation . 1999;100:1872–1878
  265. Goldberg SL , Loussararian A , De Gregorio J , et al.   Predictors of diffuse and aggressive intrastent restenosis . J Am Coll Cardiol . 2001;37:1019–1025
  266. Elezi S , Kastrati A , Hadamitzky M , et al.   Clinical and angiographic follow-up after balloon angioplasty with provisional stenting for coronary in-stent restenosis . Catheter Cardiovasc Interv . 1999;48:151–156
  267. Radke PW , Kaiser A , Frost C , et al.   Outcome after treatment of coronary in-stent restenosis (results from a systematic review using meta-analysis techniques) . Eur Heart J . 2003;24:266–273
  268. Albiero R , Silber S , Di Mario C , et al.   Cutting balloon versus conventional balloon angioplasty for the treatment of in-stent restenosis (results of the Restenosis Cutting Balloon Evaluation Trial (RESCUT)) . J Am Coll Cardiol . 2004;43:943–949
  269. Waksman R , Bhargava B , White L , et al.   Intracoronary beta-radiation therapy inhibits recurrence of instent restenosis . Circulation . 2000;101:1895–1898
  270. Waksman R , Ajani AE , White RL , et al.   Five-year follow-up after intracoronary gamma radiation therapy for in-stent restenosis . Circulation . 2004;109:340–344
  271. Hausleiter J , Kastrati A , Mehilli J , et al.   Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis (the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial) . Circulation . 2004;110:790–795
  272. Neumann FJ , Desmet W . The TROPICAL Study: A multicenter non-randomised study of the CYPHER sirolimus-eluting stent in the treatment of patients with an in-stent restenotic native coronary lesion. Presented at EuroPCR 2004: The Paris Course on Revascularization . 2004; May 25-28 Paris, France
  273. Alameddine FF , Costa M , Katz S , et al.   CYPHER™ sirolimus-eluting Bx Velocity stent is safe and effective for the treatment of in-stent restenosis . J Am Coll Cardiol . 2005;45(3):44A
  274. Kastrati A , Mehilli J , von Beckerath N , et al.   Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis (a randomized controlled trial) . JAMA . 2005;293(2):165–171
  275. Waksman R , Torguson R , Ajani AE , et al.   Drug eluting stents versus repeat vascular brachythreapy for patients with recurrence of in-stent restenosis who failed radiation therapy . J Am Coll Cardiol . 2005;45(3):44A
  276. Warth DC , Leon MB , O’Neill W , et al.   Rotational atherectomy multicenter registry (acute results, complications and 6-month angiographic follow-up in 709 patients) . J Am Coll Cardiol . 1994;24:641–648
  277. Moussa I , Ellis SG , Moseset JW , et al.   The impact of culprit lesion calcification in patients undergoing paclitaxel-eluting stent implantation (a TAXUS-IV sub study) . J Am Coll Cardiol . 2005;45(3):65A
  278. Kini AS , Kim MC , Das S , et al.   Efficacy of drug-eluting stents in the calcified lesions . J Am Coll Cardiol . 2005;45(3):65A
  279. Stenting of Coronary Arteries in Non-Stress/Benestent Disease (SCANDSTENT) trial. Presented by Henning Kelbaeck at the 2005 ACC Scientific Sessions, Orlando, FL, USA.
  280. Hammond T , Tanguay JF , Bourassa MG . Management of coronary artery disease (therapeutic options in patients with diabetes) . J Am Coll Cardiol . 2000;36:355–365
  281. Cohen RA . Dysfunction of vascular endothelium in diabetes mellitus . Circulation . 1993;87(suppl V): V-67-76
  282. Aronson D , Bloomgarden Z , Rayfield EJ . Potential mechanisms promoting restenosis in diabetic patients . J Am Coll Cardiol . 1996;27:528–535
  283. Nahser PJ , Brown RE , Oskarsson H , et al.   Maximal coronary flow reserve and metabolic coronary vasodilation in patients with diabetes mellitus . Circulation . 1995;91:635–640
  284. Yokoyama I , Momomura SI , Ohtake T , et al.   Reduced myocardial flow reserve in non-insulin-dependent diabetes mellitus . J Am Coll Cardiol . 1997;30:1472–1477
  285. Nitenberg A , Paycha F , Ledoux S , et al.   Coronary artery responses to physiological stimuli are improved by deferoxamine but not by L-arginine in non-insulin-dependent diabetic patients with angiographically normal coronary arteries and no other risk factors . Circulation . 1998;97:736–743
  286. Lorenzi M , Cagliero E , Toledo S . Glucose toxicity for human endothelial cells in culture. Delayed replication, disturbed cell cycle, and accelerated death . Diabetes . 1985;34:621–627
  287. Winocour PD , Richardson M , Kinlough-Rathbone RL . Continued platelet interaction with de-endothelialized aorta associated with slower re-endothelialization and more extensive intimal hyperplasia in spontaneously diabetic BB Wistar rats . Int J Exp Pathol . 1993;74:603–613
  288. Winocour PD . Platelet abnormalities in diabetes mellitus. Diabetes 1992;41(suppl 2):26-31. Strano A, Davi G, Patrono C. In vivo platelet activation in diabetes mellitus (review) . Semin Thromb Haemost . 1991;17:422–425
  289. Jilma B , Fasching P , Ruthner C , et al.   Elevated circulating P-selectin in insulin dependent diabetes mellitus . Thromb Haemost . 1996;76:328–332
  290. Tschoepe D , Roesen P , Esser J , et al.   Large platelets circulate in an activated state in diabetes mellitus . Semin Thromb Haemost . 1991;17:433–438
  291. Davi G , Catalano I , Averna M , et al.   Thromboxane biosynthesis and platelet function in type II diabetes mellitus . N Engl J Med . 1990;322:1769–1774
  292. Ceriello A . Coagulation activation in diabetes mellitus (a role of hyperglycemia and therapeutic prospects) . Diabetologia . 1993;36:1119–1125
  293. Stout RW . Insulin and atheroma (20-year perspective) . Diabetes Care . 1990;13:631–654
  294. Nordt TK , Sawa H , Sobel BE . Induction of plasminogen activator inhibitor type-1 (PAC-1) by proinsulin and insulin in vivo . Circulation . 1995;91:764–770
  295. Sobel BE , Woodcock-Mitchell J , Schneider DJ , et al.   Increased plasminogen activator inhibitor type-1 in coronary artery atherectomy specimens from type-2 diabetic compared with nondiabetic patients . Circulation . 1998;97:2213–2221
  296. Silva JA , Escobar A , Collins TJ , et al.   Unstable angina (a comparison of angioscopic findings between diabetic and nondiabetic patients) . Circulation . 1995;92:1731–1736
  297. Reaven GM . Role of insulin resistance in human disease . Diabetes . 1988;37:1595–1607
  298. Stern MP . Do non-insulin-dependent diabetes mellitus and cardiovascular disease share common antecedents? . Ann Intern Med . 1996;93:1780–1783
  299. Godsland IK , Stevenson JC . Insulin resistance (syndrome or tendency?) . Lancet . 1995;346:100–103
  300. Laakso M , Sarlund H , Salonen R , et al.   Asymptomatic atherosclerosis and insulin resistance . Arterioscler Thromb . 1991;11:1068–1076
  301. Wingard DL , Barrett-Connor EL , Ferrara A . Is insulin really a heart disease risk factor? . Diabetes Care . 1995;18:1299–1304
  302. Ruige JB , Assendelft WJJ , Dekker JM , et al.   Insulin and risk of cardiovascular disease. A metaanalysis . Circulation . 1998;97:996–1001
  303. Young MH , Jeng CY , Sheu WHH , et al.   Insulin resistance, glucose intolerance, hyperinsulinemia and dyslipidemia in patients with angiographically demonstrated coronary disease . Am J Cardiol . 1993;72:458–460
  304. Agewall S , Fagerberg B , Attwall S , et al.   Carotid artery wall intima-media thickness is associated with insulin-mediated glucose disposal in men at high and low coronary risk . Stroke . 1995;26:956–960
  305. Bressler P , Bailey SR , Matsuda M , et al.   Insulin resistance and coronary disease . Diabetologia . 1996;39:1345–1350
  306. Howard G , O’Leary DH , Zaccaro D , et al.  IRAS Investigators   Insulin sensitivity and atherosclerosis . Circulation . 1996;93:1809–1817
  307. Reaven GM . Hypertension and associated metabolic abnormalities- the role of insulin resistance and the sympathoadrenal system . N Engl J Med . 1996;334:374–381
  308. Stein B , Weintraub WS , Gebhart SSP , et al.   Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty . Circulation . 1995;91:979–989
  309. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators . Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease . N Engl J Med . 1996;335:217–225
  310. The BARI Investigators . Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) . Circulation . 1997;96:1761–1769
  311. The CABRI Trial Participants . First-year results of CABRI (Coronary Angioplasty versus Bypass Revascularization Investigation) . Lancet . 1995;346:1179–1184
  312. Kip KE , Faxon DP , Detre KM , et al.   Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry . Circulation . 1996;94:1818–1825
  313. O’Neill WW . Multivessel balloon angioplasty should be abandoned in diabetic patients . J Am Coll Cardiol . 1998;31:20–22
  314. Weintraub WS , Stein B , Kosinski A , et al.   Outcome of coronary bypass surgery versus coronary angioplasty in diabetic patients with multivessel coronary artery disease . J Am Coll Cardiol . 1998;31:10–19
  315. Detre KM , Guo P , Holubkov R , et al.   Coronary revascularization in diabetic patients. A comparison of the randomized and observational components of the Bypass Angioplasty Revascularization Investigation (BARI) . Circulation . 1999;99:633–640
  316. Kuntz RE . Importance of considering atherosclerosis progression when choosing a coronary revascularization strategy. The diabetes percutaneous transluminal coronary angioplasty dilemma . Circulation . 1999;99:847–851
  317. Morris JJ , Smith LR , Jones RH , et al.   Influence of diabetes and mammary artery grafting on survival after coronary bypass . Circulation . 1991;84(suppl 3): III-275-84
  318. Smith LR , Harrell FE , Rankin JS , et al.   Determinants of early versus late cardiac death in patients undergoing coronary artery bypass graft surgery . Circulation . 1991;84(suppl III): III-245-53
  319. Alderman EL , Corley SD , Fisher LD , et al.   The CASS Participating Investigators and Staff. Five-year angiographic follow-up of factors associated with progression of coronary artery disease in the Coronary Artery Surgery Study (CASS) . J Am Coll Cardiol . 1993;22:1141–1154
  320. Herlitz J , Karlson BW , Wognsen GB , et al.   Mortality and morbidity in diabetic and non-diabetic patients during a 2-year period after coronary artery bypass grafting . Diabetes Care . 1996;19:698–703
  321. Barsness GW , Peterson ED , Ohman EM , et al.   Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty . Circulation . 1997;96:2551–2556
  322. Van Belle E , Bauters C , Hubert E , et al.   Restenosis rates in diabetic patients (a comparison of coronary stenting and balloon angioplasty in native coronary vessels) . Circulation . 1997;96:1454–1460
  323. Wong SC , Baim DS , Schatz RA , et al.   Immediate results and late outcomes after stent implantation in saphenous vein graft lesions (the multicenter U.S. Palmaz-Schatz stent experience) . J Am Coll Cardiol . 1995;26:704–712
  324. Carrozza JP , Kuntz RE , Fishman RF , et al.   Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus . Ann Intern Med . 1993;118:344–349
  325. Elezi S , Schuhlen H , Wehinger A , et al.   Stent placement in diabetic versus non-diabetic patients (six month angiographic follow-up [abstract]) . J Am Coll Cardiol . 1997;29:188A
  326. Okoi H , Nosaka T , Kimura T , et al.   Coronary stenting in diabetic patients (early and follow-up results [abstract]) . J Am Coll Cardiol . 1997;29:455A
  327. Van Belle E , Perie M , Braune D , et al.   Effects of coronary stenting on vessel patency and longterm clinical outcome after percutaneous coronary revascularization in diabetic patients . J Am Coll Cardiol . 2002;40:410–417
  328. Rozenman Y , Sapoznikov D , Mosseri M , et al.   Long-term angiographic follow-up of coronary balloon angioplasty in patients with diabetes mellitus . J Am Coll Cardiol . 1997;30:1420–1425
  329. Savage MP , Fischman DL , Schatz RA , et al.   Coronary intervention in the diabetic patient (improved outcome following stent implantation compared with balloon angioplasty) . Clin Cardiol . 2002;25:213–217
  330. Moses JW , Leon MB , Popma JJ , et al.   Matched comparison of direct stenting to predilation with the sirolimus-eluting Bx Velocity™ stent . J Am Coll Cardiol . 2004;43:97A
  331. Sabate M. DIABETes and sirolimus Eluting Stent trial: The DIABETES Trial. Presented at Transcatheter Therapeutics 2004, Sept 27. Washington, DC.
  332. Jiménez-Quevedo P , Sabaté M , Angiolillo DJ , et al.   The Diabetes (DIABETes and Sirolimus Eluting Stent) Trial (one-year clinical results) . J Am Coll Cardiol . 2005;45(3):70A
  333. Jiménez-Quevedo P , Sabaté M , Angiolillo DJ , et al.   Sirolimus-eluting stent to prevent restenosis in diabetic patients with de novo coronary stenoses: the diabetes trial. Nine-month intravascular ultrasound results . J Am Coll Cardiol . 2005;45(3):71A
  334. Villa A , Jimenez R , Diego A , et al.   Comparison of rapamycin and paclitaxel drug-eluting stents in diabetic patients. Preliminary results of the RECORD trial . Am J Cardiol . 2004;94(suppl 6A):209E
  335. Cheek B , Rohrbeck S , Kalil D , et al.   Drug-eluting stents in diabetic patients (clinical outcomes from the strategic transcatheter evaluation of new therapies (STENT) group) . J Am Coll Cardiol . 2005;45(3):73A
  336. Lotan C , Sousa E , Urban P , et al.   Sirolimus eluting stent implantation in routine clinical practice (a 12-month follow-up report from the international e-CYPHER registry) . J Am Coll Cardiol . 2004;43:97A
  337. Commeau P. Safety and efficiency registry of Bx Velocity CypherTM stent in the Revascularization of patients with significant risk of restenosis (BRIDGE) registry. Presented at the 16th Annual Scientific Symposium—Transcatheter Cardiovascular Therapeutics. September 29, 2004. Washington, DC.
  338. Kuchulakanti P , Canos DA , Kim S , et al.   Impact of treatment of coronary artery disease with sirolimus-eluting stents on outcomes of diabetic compared with non-diabetic patients . J Am Coll Cardiol . 2005;45(3):73A
  339. Hermiller JB, Raizner A, Cannon L, et al. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS IV trial. J Am Coll Cardiol (in press).
  340. Dawkins KD. TAXUS VI: paclitaxel-eluting stents in the treatment of longer lesions. Focus on patients with diabetes. Paper presented at the European Society of Cardiology Congress 2004, 29 August-1 September, Munich, Germany.
  341. Finn AV , Palacios IF , Kastrati A , et al.   Drug-eluting stents for diabetes mellitus (a rush to judgment?) . J Am Coll Cardiol . 2005;45(4):479–483
  342. Gershlick AH , Lotan C , Urban P , et al.   Treatment of acute myocardial infarction with sirolimus-eluting coronary stents (midterm results from the e-CYPHER international registry) . Am J Cardiol . 2004;94(suppl 6A):208E
  343. Gupta N , Debsikdar J , Brodie BR , et al.   Drug eluting stents vs bare metal stents in patients with ST elevation myocardial infarction (results from the STENT registry) . Am J Cardiol . 2004;94(suppl 6):11E
  344. Newell M , Sigakis C , Larson DM , et al.   Sirolimus-eluting stents are safe and effective for acute and long-term management of ST-segment elevation myocardial infarction in the “Real World” . J Am Coll Cardiol . 2005;45(3):24A
  345. Perin EC . Choosing a drug-eluting stent (a comparison between CYPHER and TAXUS) . Rev Cardiovasc Med . 2005;6(suppl 1):S13–S21
  346. Goy JJ , Stauffer JC , Siegenthaler M , et al.   A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology (the TAXi trial) . J Am Coll Cardiol . 2005;45(2):308–311
  347. The Prospective Randomized Multi-Center Head-to-Head Comparison of the Sirolimus-Eluting Stent (Cypher) and the Paclitaxel-Eluting Stent (Taxus)(REALITY) trial. Presented by Dr. Marie-Claude Morice at the 2005 ACC Scientific Sessions, Orlando, FL.
  348. The Sirolimus-eluting Stent compared with Paclitaxel-eluting Stent for Coronary Revascularization(SIRTAX) trial. Presented by Dr. Stephan Windecker at the 2005 ACC Scientific Sessions, Orlando, FL.
  349. The Paclitaxel-Eluting Stent Versus Sirolimus-Eluting Stent for the Prevention of Restenosis in Diabetic Patients with Coronary Artery Disease(ISAR DIABETES) trial. Presented by Dr. Adnan Kastrati at the 2005 ACC Scientific Sessions, Orlando, FL.
  350. Ong AT, Hoye A, Aoki J, et al. The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population. One-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. J Am Coll Cardiol 2005;45: (in press).
  351. Grube E , Sonoda S , Ikeno F , et al.   Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer . Circulation . 2004;109(18):2168–2171
  352. Grube E , Costa R , Mehran R . Everolimus-eluting stents for the prevention of restenosis (results of the FUTURE II trial) . J Am Coll Cardiol . 2004;43(suppl A):86A
  353. Grube E , Buellesfeld L . Everolimus for stent-based intracoronary applications . Rev Cardiovasc Med . 2004;5(suppl 2):S3–S8
  354. Serruys PW. SPIRIT FIRST: everolimus-eluting durable polymer on the ML VISION Platform—baseline and 6-month follow-up. Presented at The Transcatheter Cardiovascular Therapeutics Conference 2004. September 27-October 1, 2004, Washington, DC.
  355. Serruys PW . SPIRIT FIRST clinical trial (a clinical evaluation of the Guidant MULTI-LINK VISION-E® RX Drug Eluting Stent System in the treatment of patients with de novo native coronary artery lesions) . Am J Cardiol . 2004;94(suppl 6A):70E
  356. Wieneke H , Dirsch O , Sawitowski T , et al.   Synergistic effects of a novel nanoporous stent coating and tacrolimus on intima proliferation in rabbits . Catheter Cardiovasc Interv . 2003;60:399–407
  357. Grube E , Buellesfeld L . Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents . Herz . 2004;29:162–166
  358. Grube E. Final tacrolimus outcomes in native coronaries and saphenous vein grafts: PRESENT & EVIDENT. Presented at the ACC Meeting, Chicago, March 30-April 2, 2003.
  359. Bartorelli A. JUPITER I: first-in-man experience with the tacrolimus-eluting JANUS CarboStent. Presented at EuroPCR 2004, the Paris Course on Revascularization. May 25-28, 2004, Paris, France.
  360. Meredith IT, ENDEAVOR I: safety and efficacy of the ABT-578-coated endeavor stent; 12-month follow-up. Presented at EuroPCR, Paris, May 25-28, 2004.
  361. Randomized comparison of the endeavor ABT-578 drug eluting stent with a bare metal stent for coronary revascularization. Presented by Dr. William Wijns at the 2005 ACC Scientific Sessions, Orlando, FL.
  362. Virmani R , Farb A , Kolodgie FD . Histopathologic alterations after endovascular radiation and antiproliferative stents (similarities and differences) . Herz . 2002;27:1–6
  363. Babinska A , Markell MS , Salifu MO , et al.   Enhancement of human platelet aggregation and secretion induced by rapamycin . Nephrol Dial Transplant . 1998;13:3153–3159
  364. Ong AT , Hoye A , Aoki J , et al.   Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation . J Am Coll Cardiol . 2005;45:947–953
  365. Bavry AA , Kumbhani DJ , Helton TJ , et al.   What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention? . J Am Coll Cardiol . 2005;45:941–946
  366. Moreno R , Fernandez C , Hernandez R , et al.   Drug-eluting stent thrombosis (results from a pooled analysis including 10 randomized studies) . J Am Coll Cardiol . 2005;45:954–959
  367. Pasceri V , Granatelli A , Pristipino C , et al.   High-risk of thrombosis of Cypher stent in patients not taking ticlopidine or clopidogrel (abstr) . Am J Cardiol . 2003;92:91L
  368. Orford JL , Lennon R , Melby S , et al.   Frequency and correlates of coronary stent thrombosis in the modern era (analysis of a single center registry) . J Am Coll Cardiol . 2002;40:1567–1572
  369. Virmani R , Guagliumi G , Farb A , et al.   Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent. Should we be cautious? . Circulation . 2004;109:r38–r42
  370. Cutlip DE , Baim DS , Ho KKL , et al.   Stent thrombosis in the modern era. A pooled analysis of multicenter coronary stent clinical trials . Circulation . 2001;103:1967–1971
  371. Chieffo A , Bonizzoni E , Orlic D , et al.   Intraprocedural stent thrombosis during implantation of sirolimus-eluting stents . Circulation . 2004;109:2732–2736
  372. Stankovic G , Orlic D , Chieffo A , et al.   Predictors of creatinine kinase MB enzyme elevation after percutaneous coronary intervention using sirolimus-eluting stents (abstr) . Am J Cardiol . 2003;92:182L
  373. Cutlip DE , Baim DS , Ho KK , et al.   Stent thrombosis in the modern era (a pooled analysis of multicenter coronary stent clinical trials) . Circulation . 2001;103:1967–1971
  374. Cheneau E , Leborgne L , Mintz GS , et al.   Predictors of subacute stent thrombosis (results of a systematic intravascular ultrasound study) . Circulation . 2003;108:43–47
  375. Orford JL , Lennon R , Melby S , et al.   Frequency and correlates of coronary stent thrombosis in the modern era (analysis of a single center registry) . J Am Coll Cardiol . 2002;40:1567–1572
  376. Gum PA , Kottke-Marchant K , Welsh PA , et al.   A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease . J Am Coll Cardiol . 2003;41:961–965
  377. Lau WC , Gurbel PA , Watkins PB , et al.   Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance . Circulation . 2004;109:166–171

 Dr. Salam, Dr. Suwaidi, and Dr. Holmes have no conflicts of interest to disclose.

PII: S0146-2806(05)00150-7

doi: 10.1016/j.cpcardiol.2005.09.002

Current Problems in Cardiology
Volume 31, Issue 1 , Pages 8-119 , January 2006

Article Tools